← All trials
NCT05369390
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 11, 2022
- Primary completion
- Jun 5, 2023
- Completion date
- Jul 10, 2023
- First posted
- May 11, 2022
- Last posted
- Nov 25, 2022
- Enrollment
- 116
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Novo NordiskLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.